Delhi High Court Upholds Public Health, Awards Johnson & Johnson Crores in Damages for Medical Device Counterfeiting - 2025-03-12

Legal News & Court Updates.

```markdown

Delhi High Court Awards Landmark Damages to Johnson & Johnson in Counterfeit Medical Device Case

New Delhi, March 11, 2025 – The Delhi High Court has delivered a significant judgment in favor of Johnson & Johnson , awarding substantial compensatory and exemplary damages totaling ₹3.34 Crores against Pritamdas Arora and M/s Medserve for the deliberate counterfeiting and sale of surgical medical devices under the plaintiff’s registered trademarks ‘SURGICEL’ and ‘ETHICON’. Justice AmitBansal presided over the case, emphasizing the grave threat posed to public health by the defendants' actions.

Case Background: Counterfeit ing Network Uncovered

Johnson & Johnson , a global healthcare giant, filed a commercial suit in 2019 seeking a permanent injunction against Pritamdas Arora and M/s Medserve, along with other reliefs, for trademark infringement, passing off, and selling counterfeit medical products. The case originated from the discovery of counterfeit ‘SURGICEL’ devices at the University of Kentucky Medical Center in the USA, which were traced back through a complex supply chain to the defendants operating from New Delhi.

Investigations revealed a sophisticated international network orchestrated by the defendants, involving the manufacture of counterfeit surgical devices in countries like Turkey and China, repackaging in India with falsified labels, and distribution across at least nine countries. Evidence presented included seized documents, electronic data, and Local Commissioner reports detailing the extent of the illicit operation.

Plaintiff's Arguments: Evidence of Deliberate Infringement and Public Risk

Represented by Ms. Nancy Roy , the plaintiff presented compelling evidence demonstrating the defendants’ deliberate and mala fide conduct. Key arguments included:

• Trademark Infringement and Passing Off: The defendants were found to be using Johnson & Johnson ’s registered trademarks ‘SURGICEL’, ‘ETHICON’, and ‘ LIGACLIP ’ without authorization, including replicating the plaintiff's unique trade dress.
• Counterfeit Products and Public Health Risk: Counterfeit devices were proven to be substandard, non-sterile, inadequately oxidized, and contaminated, posing a severe risk of infections and complications for patients undergoing surgery. The court noted the defendants' blatant disregard for public safety, highlighted by intercepted communications where bribery was suggested over corrective action upon receiving complaints about infected products.
• International Scale of Operation: Evidence showed the defendants distributed approximately 250,000 counterfeit medical devices internationally between 2017 and 2019, utilizing foreign bank accounts and Hawala transactions to evade Indian financial regulations and taxes.
• Active Involvement of Both Defendants: While Defendant No. 2, Ritika Arora (wife of Defendant No. 1), initially claimed to be a homemaker uninvolved in the business, the court found evidence of her active participation in repackaging counterfeit products and managing logistics.

Defendants' Stance: Denial and Evasion

Despite initially filing a written statement with bare denials and vague assertions, the defendants ceased to appear before the court proceedings after initial stages. They failed to offer any plausible defense or explanation for the overwhelming evidence against them. The court noted their consistent evasion and non-cooperation, even leading to the issuance of non-bailable warrants and directives to multiple government agencies to locate them.

Court's Analysis and Reliance on Legal Precedents

Justice Bansal meticulously analyzed the evidence, including Local Commissioner reports, seized documents, and electronic data, which were deemed admissible as evidence due to the defendants' initial consent and lack of challenge.

The court emphasized the principle that damages in cases of deliberate trademark infringement should be stringent, citing Koninlijke Philips N.V. & Anr. v. Amazestore & Ors and Cartier International A.G. v. Gaurav Bhatia . Regarding exemplary damages, the judgment referenced Rookes v. Barnard , Cassell & Co Ltd v Broome , and Hindustan Unilever Limited v. Reckitt Benckiser India Limited , underscoring that exemplary damages serve to punish egregious misconduct and deter future offenses, especially where public health is endangered. Principles for awarding costs were drawn from Uflex Limited v. Government of Tamil Nadu and Ors .

Pivotal Excerpts from the Judgment

The court highlighted the severe implications of the defendants' actions, stating:

> “ Counterfeit ing of medical devices is not merely a case of trade mark infringement, it is a grave offence that endangers the lives of people. The defendants’ conduct demonstrates a deliberate effort to mislead the public, jeopardize the consumer safety and exploit consumer trust for financial gain. ”

Regarding the deliberate nature of the infringement and the need for substantial damages, the court observed:

> “ In my view, the counterfeit medical products sold by the defendants pose a significant threat to public health… The defendants’ deliberate and fraudulent acts have also caused irreparable harm to the plaintiff’s goodwill and market reputation. ”

Final Verdict and Implications

The Delhi High Court decreed in favor of Johnson & Johnson , granting a permanent injunction against the defendants from infringing the plaintiff’s trademarks and engaging in counterfeiting activities. The court awarded:

• Compensatory Damages: ₹2,34,82,986/- (calculated at 25% of the estimated sales of counterfeit goods).
• Exemplary Damages: ₹1,00,00,000/- to punish the defendants' egregious conduct and deter similar actions.
• Costs: To be determined separately based on the plaintiff's bill of costs.

This judgment serves as a strong deterrent against the counterfeiting of medical devices in India, underscoring the judiciary's commitment to protecting public health and upholding intellectual property rights. The hefty damages awarded reflect the severity with which the court views such offenses, particularly when they directly endanger patient safety. ```